Title:
COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANAPLASTIC LYMPHOMA KINASE AND ROS1 KINASE
Document Type and Number:
WIPO Patent Application WO/2024/059525
Kind Code:
A3
Abstract:
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for anaplastic lymphoma kinase (ALK) and ROS1. These compounds are useful in methods for the targeted degradation of ALK and ROS1 through the use of the bifunctional compounds that link a ubiquitin ligase - binding moiety to a ligand that is capable of binding to ALK and ROS1 which can be utilized in the treatment of disorders modulated by ALK and ROS1.
Inventors:
WANG GUANGDI (US)
PENG XIANYOU (US)
PENG XIANYOU (US)
Application Number:
PCT/US2023/073910
Publication Date:
April 18, 2024
Filing Date:
September 12, 2023
Export Citation:
Assignee:
ENDOTARGET INC (US)
International Classes:
C07D401/12; C07D401/14; C07D403/14; C07D417/14; A61K45/06; A61K47/54; A61K47/55; A61P35/00
Attorney, Agent or Firm:
NGUYEN, Quang, D. et al. (US)
Download PDF: